A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
Phase: Phase II-III clinical trials
Principal Investigator: Dott.ssa Ducceschi Monika
Main Facility: Oncologia Chirurgica Ginecologica
Drug: MK-2870, also known as Sacituzumab tirumotecan
Pathologies: Cervical tumor
Phase 3 clinical study evaluating Sacituzumab tirumotecan (MK-2870), an antibody–drug conjugate (ADC) that binds to the TROP2 protein on tumor cells, is internalized, and releases a topoisomerase I inhibitor (KL610023) that blocks DNA replication, leading to cell-cycle arrest and tumor cell death, in patients with persistent, recurrent, or newly diagnosed metastatic cervical cancer.The study includes two parts:
an induction phase with Paclitaxel, cisplatin or carboplatin, Pembrolizumab, and Bevacizumab;
followed by a maintenance phase with MK-2870, Pembrolizumab, and Bevacizumab.
This is followed by an open-label, randomized 1:1 maintenance phase.
Last update: 21/04/2026